Aaron Fox-Collis - 31 Jan 2023 Form 3 Insider Report for Fresh Tracks Therapeutics, Inc.

Role
VP of Finance & CAO
Signature
/s/ Griffin D. Foster, Attorney-in-Fact for Aaron Fox-Collis (power of attorney filed herewith)
Issuer symbol
N/A
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
3
Filing time
01 Dec 2023, 16:15:47 UTC
Next filing
04 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FRTX Common Stock 110 31 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FRTX Stock Option (right to buy) 31 Jan 2023 Common Stock 195 $36.00 Direct F2
holding FRTX Stock Option (right to buy) 31 Jan 2023 Common Stock 174 $40.50 Direct F2
holding FRTX Stock Option (right to buy) 31 Jan 2023 Common Stock 800 $11.70 Direct F2
holding FRTX Stock Option (right to buy) 31 Jan 2023 Common Stock 2,222 $6.03 Direct F2
holding FRTX Restricted Stock Units 31 Jan 2023 Common Stock 8,000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 74 shares acquired under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan.
F2 The stock options vested 25% on this date, the first anniversary of the date of grant, and the remainder are vesting in equal monthly installments over the following three years.
F3 The restricted stock units vest in full on January 24, 2024, the first anniversary of the grant date.
F4 Each restricted stock unit represents a contingent right to receive one share of issuer common stock upon settlement.

Remarks:

Exhibit 24 - Power of Attorney